In a small Phase II trial, people with cocaine use disorder who took mavoglurant used the drug less often over a three month ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

The Eli Lilly drug caused a major drop in the blood levels of Lp(a), but further research is needed to show that it will ...

In an exclusive interview with NBC News, President Donald Trump said there were methods that would allow him to seek a third ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

Discover how the experimental drug lepodisiran dramatically lowers lipoprotein(a) levels, potentially transforming treatment ...